Definium Therapeutics, Inc 6-K, filed Oct 4, 2021
Definium Therapeutics, Inc. (DFTX)
About this 6-K
Definium Therapeutics, Inc filed this 6-K on October 4, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2021
Commission File Number: 001-40360
MIND MEDICINE (MINDMED) INC.
(Name of registrant)
One World Trade Center
Suite 8500
New York, New York 10007
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| ¨ Form 20-F | x Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MIND MEDICINE (MINDMED) INC. | |||
| (Registrant) | |||
| Date: October 4, 2021 | By: | /s/ Robert Barrow | |
| Name: | Robert Barrow | ||
| Title: | Chief Executive Officer | ||
Form 6-K Exhibit Index
| Exhibit Number |
Document Description | |
| 99.1 | Material Change Report dated October 4, 2021. |
Exhibit 99.1
Form 51-102F3
Material Change Report
| Item 1 | Name and Address of Company |
Mind Medicine (MindMed) Inc. (the “Company”)
1166 Alberni Street, Suite 1604,
Vancouver, British Columbia
V6E 3Z
| Item 2 | Date of Material Change |
September 29, 2021
| Item 3 | News Release |
On September 30, 2021, a news release was disseminated through the newswire services of GlobalNewswire and subsequently filed on SEDAR at www.sedar.com.
| Item 4 | Summary of Material Change |
On September 29, 2021, the Company appointed Andreas Krebs and Carol Vallone as directors of the Company and Bruce Linton ceased to be a director of the Company.
| Item 5 | Full Description of Material Change |
| 5.1 | Full Description of Material Change |
On September 29, 2021, the Company appointed Andreas Krebs and Carol Vallone as directors of the Company and Bruce Linton ceased to be a director of the Company.
| 5.2 | Disclosure for Restructuring Transactions |
Not Applicable.
| Item 6 | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not Applicable.
| Item 7 | Omitted Information |
Not Applicable.
| Item 8 | Executive Officer |
For further information, please contact Rob Barrow, Chief Executive Officer of the Company, at 212-220-6633.
| Item 9 | Date of Report |
October 4, 2021.